Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIUZX3)

Drug Name
LTD4 Drug Info
Synonyms
S-[(4S,5R,6E,8E,10Z,13Z)-1-Carboxy-4-hydroxynonadeca-6,8,10,13-tetraen-5-yl]cysteinylglycine; 5(S)-Hydroxy-6(R)-S-cysteinylglycinyl-7-trans-9-trans-11-cis-14-cis-eicosatetraenoic Acid; Leukotriene D(sub 4); (5S,6R,7E,9E,11Z,14Z)-6-({2-amino-2-[(carboxymethyl)carbamoyl]ethyl}sulfanyl)-5-hydroxyicosa-7,9,11,14-tetraenoic acid; LTD (sub 4); [3H]LTD4; [3H]-LTD4; S-[(4S,5R,6E,8E,10Z,13Z)-1-carboxy-4-hydroxynonadeca-6,8,10,13-tetraen-5-yl]cysteinylglycine; AC1O5JI4; SCHEMBL4295683; GTPL3412; BML1-E08; GTPL3353; CHEMBL1521056; DTXSID6040533; YEESKJGWJFYOOK-LDDGIIIKSA-N; 73836-78-9; LTD; leukotriene D4
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5280878
ChEBI ID
CHEBI:28666
CAS Number
CAS 73836-78-9
TTD Drug ID
DMIUZX3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Investigative Drug(s)
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Uracil nucleotide/cysteinyl leukotriene receptor (GPR17)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LTE4 DMCPB0Q Discovery agent N.A. Investigative [10]
UDP-glucose DMLT4JA Discovery agent N.A. Investigative [4]
LTC4 DM702WR Discovery agent N.A. Investigative [4]
ASN04421891 DMC82XN Discovery agent N.A. Investigative [11]
ASN04450772 DMKR69T Discovery agent N.A. Investigative [11]
ASN06917370 DMA20JP Discovery agent N.A. Investigative [11]
ASN02563583 DMEO3Y4 Discovery agent N.A. Investigative [11]
ASN04885796 DMQ0VZ8 Discovery agent N.A. Investigative [11]
⏷ Show the Full List of 8 Drug(s)
Drug(s) Targeting Leukotriene CysLT1 receptor (CYSLTR1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Montelukast DMD157S Allergic asthma CA23.0 Approved [12]
Zafirlukast DMHNQOG Asthma CA23 Approved [13]
Pranlukast DMYHDCA Allergic rhinitis CA08.0 Approved [14]
Cinalukast DMFIC0M Asthma CA23 Approved [15]
KP-496 DMCO8UZ Asthma CA23 Phase 2 [16]
BAY-X-7195 DM2XE80 Asthma CA23 Phase 2 [17]
Masilukast DMDTI0L Asthma CA23 Phase 2 [18]
LM-1507.NA DMW6VA0 Asthma CA23 Phase 2 [19]
Iralukast DMQ3RWN Asthma CA23 Phase 2 [20]
YM-57158 DMS31YW Allergic rhinitis CA08.0 Phase 1 [21]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Leukotriene CysLT2 receptor (CYSLTR2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BAY-X-7195 DM2XE80 Asthma CA23 Phase 2 [17]
AS-35 DMC2WI7 Asthma CA23 Discontinued in Phase 2 [22]
DS-4574 DM8GZWC Asthma CA23 Discontinued in Phase 2 [23]
Sulukast DMBSLZV Asthma CA23 Discontinued in Phase 2 [24]
ICI-198615 DM0195G Asthma CA23 Terminated [25]
MDL-43291 DMBIDQX Asthma CA23 Terminated [26]
LY-290154 DMPZ7AO Asthma CA23 Terminated [27]
FPL-55712 DMF1CDK Asthma CA23 Terminated [28]
LTE4 DMCPB0Q Discovery agent N.A. Investigative [29]
LTC4 DM702WR Discovery agent N.A. Investigative [3]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cysteinyl leukotriene receptor 1 (CYSLTR1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Zafirlukast DMHNQOG Asthma CA23 Approved [30]
Pranlukast DMYHDCA Allergic rhinitis CA08.0 Approved [30]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [31]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [32]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [33]
(+)-JQ1 DM1CZSJ Testicular cancer 2C80 Phase 1 [34]
PMID28870136-Compound-48 DMPIM9L N. A. N. A. Patented [31]
LTC4 DM702WR Discovery agent N.A. Investigative [30]
LTE4 DMCPB0Q Discovery agent N.A. Investigative [35]
BAYu9773 DMXQ14V Discovery agent N.A. Investigative [30]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Tumor necrosis factor (TNF)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Indomethacin DMSC4A7 Bursitis Approved [36]
Amphotericin B DMTAJQE Acne vulgaris ED80 Approved [37]
Fructose DM43AN2 Vomiting MD90 Approved [38]
Ketoprofen DMRKXPT Bursitis Approved [38]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [39]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [40]
Baclofen DM0QV1J Multiple sclerosis 8A40 Approved [41]
Gefitinib DM15F0X Colon adenocarcinoma Approved [42]
Ganciclovir DM1MBYQ Cytomegalovirus infection 1D82 Approved [43]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [44]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Interleukin-6 (IL6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methylprednisolone DM4BDON Acute adrenal insufficiency Approved [45]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [46]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [47]
Pantothenic acid DM091H2 Vitamin deficiency 5B55-5B71 Approved [48]
Indinavir DM0T3YH Human immunodeficiency virus infection 1C62 Approved [49]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [50]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [44]
Imiquimod DM1TMA3 Alopecia areata ED70.2 Approved [51]
Methimazole DM25FL8 Hyperthyroidism 5A02 Approved [52]
Methotrexate DM2TEOL Anterior urethra cancer Approved [45]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By P-selectin (SELP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [53]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [32]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [54]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [55]
Amlodipine DMBDAZV Angina pectoris BA40 Approved [56]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [57]
Asasantin DMCZIHT Cerebrovascular ischaemia 8B1Z Approved [58]
Cimetidine DMH61ZB Acid-reflux disorder DA22 Approved [59]
Rosiglitazone DMILWZR Chronic kidney disease GB61 Approved [60]
Cocaine DMSOX7I Anaesthesia 9A78.6 Approved [61]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Tumor necrosis factor receptor superfamily member 6 (FAS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [62]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [63]
Nitric Oxide DM1RBYG Hypertension BA00-BA04 Approved [64]
Methotrexate DM2TEOL Anterior urethra cancer Approved [65]
Epinephrine DM3KJBC Acute asthma CA23 Approved [66]
Quercetin DM3NC4M Obesity 5B81 Approved [67]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [68]
Fructose DM43AN2 Vomiting MD90 Approved [69]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [62]
Cyclophosphamide DM4O2Z7 Advanced cancer 2A00-2F9Z Approved [70]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Polyunsaturated fatty acid 5-lipoxygenase (ALOX5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Meclofenamic acid DM05FXR Ankylosing spondylitis FA92.0 Approved [71]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [72]
SPI-1005 DM6XFHS Reperfusion injury ND56.Z Approved [73]
Fructose DM43AN2 Vomiting MD90 Approved [69]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [74]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [75]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [57]
Loratadine DMF3AN7 Allergy 4A80-4A85 Approved [76]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [77]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [78]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leukotriene CysLT1 receptor (CYSLTR1) TTGKOY9 CLTR1_HUMAN Agonist [2]
Leukotriene CysLT2 receptor (CYSLTR2) TT0PZR5 CLTR2_HUMAN Agonist [3]
Uracil nucleotide/cysteinyl leukotriene receptor (GPR17) TTMPART GPR17_HUMAN Agonist [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Cysteinyl leukotriene receptor 1 (CYSLTR1) OT904HBN CLTR1_HUMAN Drug Response [5]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Protein Interaction/Cellular Processes [6]
P-selectin (SELP) OTWR90PK LYAM3_HUMAN Gene/Protein Processing [7]
Polyunsaturated fatty acid 5-lipoxygenase (ALOX5) OT7FOIK2 LOX5_HUMAN Regulation of Drug Effects [8]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Protein Interaction/Cellular Processes [6]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Gene/Protein Processing [9]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3412).
2 Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol Pharmacol. 1999 Sep;56(3):657-63.
3 Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. Mol Pharmacol. 2000 Dec;58(6):1601-8.
4 The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J. 2006 Oct 4;25(19):4615-27.
5 Effects of the cysteinyl leukotriene receptor antagonists pranlukast and zafirlukast on tracheal mucus secretion in ovalbumin-sensitized guinea-pigs in vitro. Br J Pharmacol. 1998 Jun;124(3):563-71. doi: 10.1038/sj.bjp.0701886.
6 Leukotriene pathways and in vitro adenotonsillar cell proliferation in children with obstructive sleep apnea. Chest. 2009 May;135(5):1142-1149. doi: 10.1378/chest.08-2102. Epub 2008 Dec 31.
7 Cysteinyl leukotrienes induce P-selectin expression in human endothelial cells via a non-CysLT1 receptor-mediated mechanism. J Pharmacol Exp Ther. 1997 May;281(2):655-62.
8 Toxicity of human monocytic THP-1 cells and microglia toward SH-SY5Y neuroblastoma cells is reduced by inhibitors of 5-lipoxygenase and its activating protein FLAP. J Leukoc Biol. 2003 Mar;73(3):369-78.
9 Expression of functional cysteinyl leukotriene receptors by human basophils. J Allergy Clin Immunol. 2005 Jul;116(1):80-7. doi: 10.1016/j.jaci.2005.03.014.
10 The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair. PLoS One. 2008;3(10):e3579.
11 In silico identification of new ligands for GPR17: a promising therapeutic target for neurodegenerative diseases. J Comput Aided Mol Des. 2011 Aug;25(8):743-52.
12 Protective potential of montelukast against hepatic ischemia/reperfusion injury in rats. J Surg Res. 2010 Mar;159(1):588-94.
13 Inhibitory effects of zafirlukast on respiratory bursts of human neutrophils. Drugs Exp Clin Res. 2002;28(4):133-45.
14 Beneficial effects of leukotriene receptor antagonists in the prevention of cedar pollinosis in a community setting. J Investig Allergol Clin Immunol. 2009;19(3):195-203.
15 Prolonged protection against exercise-induced bronchoconstriction by the leukotriene D4-receptor antagonist cinalukast. J Allergy Clin Immunol. 1997 Feb;99(2):210-5.
16 Effects of KP-496, a novel dual antagonist for leukotriene D4 and thromboxane A2 receptors, on contractions induced by various agonists in the guinea pig trachea. Allergol Int. 2006 Dec;55(4):403-10.
17 The effect of a novel leukotriene C4/D4 antagonist, BAY-x-7195, on experimental allergic reactions. Prostaglandins. 1995 Nov-Dec;50(5-6):269-85.
18 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
19 Pharmacological differences among CysLT(1) receptor antagonists with respect to LTC(4) and LTD(4) in human lung parenchyma. Biochem Pharmacol. 2002 Apr 15;63(8):1537-46.
20 Pharmacological characterization of the cysteinyl-leukotriene antagonists CGP 45715A (iralukast) and CGP 57698 in human airways in vitro. Br J Pharmacol. 1998 Feb;123(3):590-8.
21 In vitro pharmacologic profile of YM158, a new dual antagonist for LTD4 and TXA2 receptors. J Pharmacol Exp Ther. 1998 Nov;287(2):633-9.
22 Inhibition of radiolabeled leukotriene-binding by AS-35 in guinea pig lung membrane fraction. Jpn J Pharmacol. 1992 Apr;58(4):357-64.
23 Inhibitory effect of DS-4574, a mast cell stabilizer with peptidoleukotriene receptor antagonism, on gastric acid secretion in rats. Eur J Pharmacol. 1994 Apr 1;255(1-3):229-34.
24 The pharmacological evaluation of LY 170680, a novel leukotriene D4 and E4 antagonist in the guinea-pig. Br J Pharmacol. 1989 Sep;98(1):259-67.
25 Heterogeneity of binding sites for ICI 198,615 in human lung parenchyma. Biochem Pharmacol. 1992 Oct 6;44(7):1411-5.
26 Conformationally restricted leukotriene receptor antagonists: [(octahydro-2-oxo-7-tetradecylidene-2H-1-benzopyran-8-yl)thio]ace tic acids. Pharmacology. 1990;40(5):271-6.
27 DOI: 10.1021/op060036x
28 Effect of the leukotriene receptor antagonists FPL 55712, LY 163443, and MK-571 on the elimination of cysteinyl leukotrienes in the rat. Br J Pharmacol. 1991 Apr;102(4):865-70.
29 Differential signaling of cysteinyl leukotrienes and a novel cysteinyl leukotriene receptor 2 (CysLT agonist, N-methyl-leukotriene C in calcium reporter and beta arrestin assays. Mol Pharmacol. 2011 Feb;79(2):270-8.
30 A kinetic binding study to evaluate the pharmacological profile of a specific leukotriene C(4) binding site not coupled to contraction in human lun... Mol Pharmacol. 2000 Jun;57(6):1182-9.
31 Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
32 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
33 Differential contribution of the CysLTR1 gene in patients with aspirin hypersensitivity. J Clin Immunol. 2007 Nov;27(6):613-9. doi: 10.1007/s10875-007-9115-x. Epub 2007 Jul 20.
34 Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem. 2012 Dec 14;287(51):43137-55.
35 Characterization of the leukotriene D4 receptor in dimethylsulphoxide-differentiated U937 cells: comparison with the leukotriene D4 receptor in human lung and guinea-pig lung. Eur J Pharmacol. 1993 Feb 15;244(3):239-50. doi: 10.1016/0922-4106(93)90149-4.
36 Indomethacin and juglone inhibit inflammatory molecules to induce apoptosis in colon cancer cells. J Biochem Mol Toxicol. 2020 Feb;34(2):e22433. doi: 10.1002/jbt.22433. Epub 2020 Jan 9.
37 A cell impedance-based real-time in vitro assay to assess the toxicity of amphotericin B formulations. Toxicol Appl Pharmacol. 2017 Nov 1;334:18-23. doi: 10.1016/j.taap.2017.08.017. Epub 2017 Sep 1.
38 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
39 CBD Promotes Oral Ulcer Healing via Inhibiting CMPK2-Mediated Inflammasome. J Dent Res. 2022 Feb;101(2):206-215. doi: 10.1177/00220345211024528. Epub 2021 Jul 16.
40 Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
41 Anti-inflammatory effects of the GABA(B) receptor agonist baclofen in allergic contact dermatitis. Exp Dermatol. 2010 Jul 1;19(7):661-6. doi: 10.1111/j.1600-0625.2010.01076.x. Epub 2010 Feb 25.
42 Frankincense myrrh attenuates hepatocellular carcinoma by regulating tumor blood vessel development through multiple epidermal growth factor receptor-mediated signaling pathways. World J Gastrointest Oncol. 2022 Feb 15;14(2):450-477. doi: 10.4251/wjgo.v14.i2.450.
43 Sulfasalazine unveils a contact-independent HSV-TK/ganciclovir gene therapy bystander effect in malignant gliomas. Int J Oncol. 2007 Jan;30(1):283-90.
44 Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
45 Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
46 Mechanisms of dexamethasone-induced disturbed sleep and fatigue in paediatric patients receiving treatment for ALL. Eur J Cancer. 2010 Jul;46(10):1848-55. doi: 10.1016/j.ejca.2010.03.026. Epub 2010 Apr 17.
47 Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
48 Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
49 Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther. 2007;12(4):489-500.
50 ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
51 (9)-Tetrahydrocannabinol Suppresses Monocyte-Mediated Astrocyte Production of Monocyte Chemoattractant Protein 1 and Interleukin-6 in a Toll-Like Receptor 7-Stimulated Human Coculture. J Pharmacol Exp Ther. 2019 Oct;371(1):191-201. doi: 10.1124/jpet.119.260661. Epub 2019 Aug 5.
52 Blood cell oxidative stress precedes hemolysis in whole blood-liver slice co-cultures of rat, dog, and human tissues. Toxicol Appl Pharmacol. 2010 May 1;244(3):354-65. doi: 10.1016/j.taap.2010.01.017. Epub 2010 Feb 6.
53 Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation. 2003 Aug 26;108(8):939-44. doi: 10.1161/01.CIR.0000085163.21752.0A. Epub 2003 Aug 11.
54 Hemostatic abnormalities associated with acute promyelocytic leukemia and corrective effects of all-trans-retinoic acid or arsenic trioxide treatment. Chin Med J (Engl). 2000 Mar;113(3):236-40.
55 Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy. Thromb Res. 2004;113(3-4):197-204. doi: 10.1016/j.thromres.2004.03.002.
56 Platelet morphology and plasma indices of platelet activation in essential hypertension: effects of amlodipine-based antihypertensive therapy. Ann Med. 2004;36(7):552-7. doi: 10.1080/07853890410017386.
57 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
58 Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. Eur J Pharmacol. 2004 Sep 24;499(3):315-24. doi: 10.1016/j.ejphar.2004.07.114.
59 Effects of histamine 2 receptor antagonists on endothelial-neutrophil adhesion and surface expression of endothelial adhesion molecules induced by high glucose levels. J Diabetes Complications. 2007 Jan-Feb;21(1):50-5. doi: 10.1016/j.jdiacomp.2006.02.002.
60 Reduced plaque formation induced by rosiglitazone in an STZ-diabetes mouse model of atherosclerosis is associated with downregulation of adhesion molecules. Atherosclerosis. 2008 Jul;199(1):55-64. doi: 10.1016/j.atherosclerosis.2007.10.038. Epub 2008 Feb 21.
61 Cocaine activates platelets and increases the formation of circulating platelet containing microaggregates in humans. Heart. 2000 Jun;83(6):688-95. doi: 10.1136/heart.83.6.688.
62 Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
63 Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
64 Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
65 Topotecan and methotrexate alter expression of the apoptosis-related genes BCL2, FAS and BCL2L12 in leukemic HL-60 cells. Biol Chem. 2006 Dec;387(12):1629-33. doi: 10.1515/BC.2006.203.
66 Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells: modulation of Fas/Fas ligand and caspase-3 pathway. Cardiovasc Res. 2000 Feb;45(3):788-94. doi: 10.1016/s0008-6363(99)00369-7.
67 Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
68 Regulatory role of KEAP1 and NRF2 in PPAR expression and chemoresistance in human non-small-cell lung carcinoma cells. Free Radic Biol Med. 2012 Aug 15;53(4):758-68. doi: 10.1016/j.freeradbiomed.2012.05.041. Epub 2012 Jun 7.
69 Non-nutritional sweeteners effects on endothelial vascular function. Toxicol In Vitro. 2020 Feb;62:104694. doi: 10.1016/j.tiv.2019.104694. Epub 2019 Oct 23.
70 Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
71 Meclofenamate sodium is an inhibitor of both the 5-lipoxygenase and cyclooxygenase pathways of the arachidonic acid cascade in vitro. Prostaglandins Leukot Med. 1986 Aug;23(2-3):229-38.
72 Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity. Eur J Biochem. 1999 Oct 1;265(1):27-34.
73 Molecular actions of ebselen--an antiinflammatory antioxidant. Gen Pharmacol. 1995 Oct;26(6):1153-69.
74 Immediate up-regulation of the calcium-binding protein S100P and its involvement in the cytokinin-induced differentiation of human myeloid leukemia cells. Biochim Biophys Acta. 2005 Sep 10;1745(2):156-65.
75 Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
76 Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
77 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
78 Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers. Nat Commun. 2018 Sep 26;9(1):3931.